Varian’s new HyperArc™ high-definition radiotherapy technology was showcased for the first time at the 2016 annual meeting of the American Society for Radiation Oncology (ASTRO).
"This exciting new technology unlocks the potential of using highly non-coplanar treatment strategies to usher in a new era of precision in radiotherapy and radiosurgery for cancer patients," said Kolleen Kennedy, president of Varian Oncology Systems. "HyperArc is designed to automate and simplify sophisticated treatments such as stereotactic radiosurgery (SRS) and make them available to more cancer patients around the world."
HyperArc capitalizes on the unique capabilities of Varian's TrueBeam® and EDGE™ treatment platforms including the PerfectPitch™ couch. “HyperArc will use all degrees of freedom to deliver orchestrated dynamic movements of the gantry and couch for taking optimal advantage of non-coplanar beams,” says Matthias Guckenberger, MD, head of the Department of Radiation Oncology, University Hospital Zürich, Switzerland, a member of Varian’s Radiosurgery Clinical Council, which advises Varian on the development of HyperArc technology.
The HyperArc treatment delivery technology will be available as a purchasable option on TrueBeam 2.7 and EDGE 2.7. Treatment planning for HyperArc is a “Works-in-Progress” and is being developed to help planners achieve extremely compact dose distributions consistently and efficiently while maintaining patient safety.
Guckenberger and his team plan to use HyperArc to treat brain tumors as well as vertebral metastases. “We are particularly interested in using this method to treat vertebral metastases not only in the curative setting but also in the palliative setting for patients with metastatic disease. HyperArc promises to simplify the complexity of selecting different non-coplanar beam trajectories, so that we can deliver complex treatments more rapidly and more cost-effectively.”
Varian is aiming to make the HyperArc technology clinically available later this year. First generation HyperArc is designed for the radiosurgical treatment of brain metastases, with subsequent products being developed for other treatments throughout the body. Clinicians have been collaborating with Varian on the development and preliminary testing of this technology.
"In the testing we have done to date, we have found that the HyperArc technology showed a significant improvement in both the dose coverage to the targeted tumor and an associated reduction in the dose to the organs at risk," said Garry Currie, head of Radiotherapy Physics at Beatson West of Scotland Cancer Centre in Glasgow, U.K., who also serves on the Radiosurgery Clinical Counsil. "We are excited about the potential of this technology and the impact it could make in the fight against cancer."
Approximately 20 percent of newly diagnosed cancer patients will develop brain metastases. For for many, SRS is recommended as a primary treatment option. HyperArc is designed to make it possible to easily target and eradicate isolated brain metastases and eliminate the need and complications with whole brain radiation.
“HyperArc will improve radiotherapy and radiosurgery treatments for brain metastases because this technology allows clinicians to efficiently create and deliver treatment plans with a single isocenter while achieving a high dose gradient,” notes Ke Sheng, Ph.D., FAAPM, professor and vice chair, Department of Radiation Oncology, of California, Los Angeles, another member of the Radiosurgery Clinical Council. “I truly believe that HyperArc has great promise to achieve superior dosimetry, reduce side effects, and, in many cases, improve tumor control. I am delighted to work with Varian to develop this technology for patients.”
Visit the website for more information about HyperArc.